Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...

Is obesity a risk factor or a disease? This debate shapes treatments, policies, and eating disorder care. Explore its impact ...

Gaining weight during perimenopause is common. But is it preventable? Here's what doctors say: Follow their tips to avoid ...

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel ...

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

EVERYONE GET FATTER NOW!!!! refers to an exploitable meme and phrasal template featuring slightly pixellated, red, all-caps ...

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye ...

Appalachia has a rich history and gorgeous landscapes, but it has also experienced rates of cancer incidence and death ...